Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Revive Therapeutics Ltd C.RVV

Alternate Symbol(s):  RVVTF

Revive Therapeutics Ltd. is a Canada-based life sciences company. The Company is focused on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders. It is engaged in exploring the use of Bucillamine for the potential treatment of nerve agent exposure and long COVID. The Company, through its diagnostics division, is evaluating a point-of-care in vitro diagnostic device that aids in the detection of post COVID-19 conditions or Long COVID. It also advancing the development of Psilocybin-based therapeutics through various programs. The Company's subsidiaries include Revive Therapeutics Inc. (Ontario), Revive Diagnostics Inc., and Psilocin Pharma Corp. (Ontario).


CSE:RVV - Post by User

Comment by Trippedstockson May 25, 2021 3:41pm
72 Views
Post# 33261494

RE:RE:RE:That 31st site wasn't the winner!

RE:RE:RE:That 31st site wasn't the winner!
you can transfer trial data and use it as supporting documentation. How was the Phase 2 portion of the Bucillamine in mild to moderate covid completely skipped? How was a phase 1 skipped? How did they get to a phase 3 with no pre-clinical research? They had supporting safety and efficacy information of sufficient value to consider that information as equivalent to phase 1, 2 and pre-clinical results.

You know as well as I they never intended on pursuing Gout past phase 2 and had hoped to sell that IP on... Gout isn't a big market.... 30-50 million cases of influenza every year. I have already supplied my study information for RA, Bucillamine, covid and influenza.
<< Previous
Bullboard Posts
Next >>